Shikiar Asset Management Inc. Has $1.30 Million Stock Holdings in Danaher Co. (NYSE:DHR)

Shikiar Asset Management Inc. cut its holdings in Danaher Co. (NYSE:DHR) by 5.7% in the first quarter, Holdings Channel.com reports. The fund owned 6,341 shares of the conglomerate’s stock after selling 380 shares during the quarter. Shikiar Asset Management Inc.’s holdings in Danaher were worth $1,300,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. LaFleur & Godfrey LLC increased its holdings in Danaher by 1.5% in the 4th quarter. LaFleur & Godfrey LLC now owns 29,855 shares of the conglomerate’s stock valued at $6,853,000 after buying an additional 440 shares during the period. Union Bancaire Privee UBP SA bought a new stake in Danaher in the 4th quarter valued at $74,551,000. Bank Pictet & Cie Europe AG increased its holdings in Danaher by 22.8% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 192,731 shares of the conglomerate’s stock valued at $44,241,000 after buying an additional 35,730 shares during the period. Roxbury Financial LLC bought a new stake in Danaher in the 4th quarter valued at $42,000. Finally, Congress Asset Management Co. grew its holdings in shares of Danaher by 629.0% in the 4th quarter. Congress Asset Management Co. now owns 7,516 shares of the conglomerate’s stock worth $1,725,000 after purchasing an additional 6,485 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Danaher news, Chairman Steven M. Rales sold 1,250,000 shares of the business’s stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the completion of the transaction, the chairman now owns 3,105,808 shares of the company’s stock, valued at approximately $611,036,665.92. The trade was a 28.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Christopher Paul Riley sold 15,805 shares of the company’s stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total value of $3,129,390.00. Following the completion of the transaction, the executive vice president now directly owns 15,179 shares of the company’s stock, valued at $3,005,442. This represents a 51.01% decrease in their position. The disclosure for this sale can be found here. 11.10% of the stock is currently owned by company insiders.

Danaher Price Performance

NYSE:DHR opened at $200.51 on Monday. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The firm has a fifty day simple moving average of $192.80 and a 200 day simple moving average of $210.81. Danaher Co. has a 1-year low of $171.00 and a 1-year high of $281.70. The stock has a market capitalization of $143.50 billion, a PE ratio of 37.98, a P/E/G ratio of 2.66 and a beta of 0.77.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, topping analysts’ consensus estimates of $1.62 by $0.26. The firm had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.58 billion. Danaher had a net margin of 16.33% and a return on equity of 10.82%. On average, research analysts expect that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be given a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.64%. Danaher’s payout ratio is presently 24.85%.

Analyst Ratings Changes

DHR has been the topic of several analyst reports. Barclays upped their target price on shares of Danaher from $205.00 to $215.00 and gave the stock an “overweight” rating in a report on Tuesday, April 22nd. Evercore ISI lowered their target price on shares of Danaher from $240.00 to $230.00 and set an “outperform” rating on the stock in a report on Tuesday, April 22nd. TD Cowen upped their target price on shares of Danaher from $240.00 to $248.00 and gave the stock a “buy” rating in a report on Wednesday, April 23rd. Royal Bank of Canada reiterated an “outperform” rating and set a $250.00 price target on shares of Danaher in a research report on Wednesday, April 23rd. Finally, Wells Fargo & Company decreased their price objective on shares of Danaher from $240.00 to $210.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 23rd. Five analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and an average price target of $248.17.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.